Evidence map›Paper›PMID 40909954›Full record

ArticleFrontiers in oncology2025

Case Report: Hepatic infantile hemangioma malignantly transformed into hemangiosarcoma.

Xiafei Gu, Qing Tao, Zijian Lu, Jianping Liu, Zhang Zhang, Changli Lu

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiafei GuDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Qing TaoDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Zijian LuDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Jianping LiuDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Zhang ZhangDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Changli LuDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we retrospectively analyzed the clinicopathological features of a case of hepatic infantile hemangioma (HIH) that malignantly transformed into hemangiosarcoma. HIH, a congenital disease, is the most common benign tumor of the liver in children, and its malignant transformation into hepatic angiosarcoma (HAS) is rare. HIH expresses markers of vascular origin and specifically expresses glucose transporter protein isoform 1. When the malignant transformation of HAS occurs, the vascular lumens anastomose with each other and form a sieve mesh, with pseudo-papillae and solid areas, heterogeneous proliferation of tumor cells, spindle/or epithelioid morphology, heterogeneous distribution of chromatin, enlarged nuclei, and pathologic karyotypes, with strong diffuse positivity of P53 and P16, increased Ki-67 proliferative activity, suggest malignant transformation of HAS. Imaging is the preferred examination method for HIH; however, the presence or absence of characteristic changes in HAS is unclear. There is no uniform treatment guideline for this type of tumor, and a reasonable individualized treatment plan should be formulated according to the specific conditions of the children. There is a lack of case reports of the malignant transformation of HIH into HAS. It is unclear whether HIH treatment should be still extended, and the prognosis is also unclear; therefore, more case reports are needed to accumulate experience.

Indexed as

hemangiosarcomainfantile hemangiomalivermalignant transformationtumor

Identifiers

PMID40909954
PMCPMC12405355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.